{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:10:31Z","timestamp":1777417831097,"version":"3.51.4"},"reference-count":60,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[1992,7,1]],"date-time":"1992-07-01T00:00:00Z","timestamp":709948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1992,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To discuss strategies available for the treatment of herpesvirus infections in individuals infected with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Information was obtained from controlled and uncontrolled clinical trials, abstracts, conference proceedings, and review articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Emphasis was placed on controlled investigations in subjects infected with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Data from human studies were extracted by the author and evaluated according to the patient population studied, sample size, dosage regimen, and therapeutic response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Herpes group viruses are common opportunistic pathogens in HIV-infected individuals. Zoster, caused by varicella-zoster virus (VZV), is an early indication of the loss of cell-mediated immunity and HIV disease progression. Anorectal mucocutaneous disease is the most common manifestation caused by herpes simplex virus (HSV). Acyclovir is the drug of choice for treatment of both VZV and HSV infections. Cytomegalovirus (CMV) is the most common life-threatening viral infection in patients with AIDS; retinitis is the most frequent clinical manifestation. The response rate of CMV retinitis to initial treatment with either ganciclovir or foscarnet is equivalent, approximately 60\u201390 percent. Recent data suggest that the survival benefit may be greater with foscarnet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Advances in the development and application of antiviral drugs for herpes group viruses have made treatment and, in some cases, prevention of infections possible. Future efforts, aimed at earlier intervention and suppression of latent virus, may offer additional improvement in quality of life for the HIV-infected individual.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/106002809202600720","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T07:41:04Z","timestamp":1483688464000},"page":"955-962","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of Herpesvirus Infections in Hiv-Infected Individuals"],"prefix":"10.1177","volume":"26","author":[{"given":"Courtney V.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1992,7,1]]},"reference":[{"key":"bibr1-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105093241906"},{"key":"bibr2-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.5.858"},{"key":"bibr3-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-99-2-151"},{"key":"bibr4-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90365-5"},{"key":"bibr5-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900703"},{"key":"bibr6-106002809202600720","first-page":"316","volume-title":"The medical management of AIDS","author":"Drew WL","year":"1990","edition":"2"},{"key":"bibr7-106002809202600720","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0002-9343(88)90508-6","volume":"85","author":"Huff JC","year":"1988","journal-title":"Am J Med"},{"key":"bibr8-106002809202600720","unstructured":"Blum MR, Weller S, de Miranda P, Cederberg D, Burnette T, Smiley L. Single and multiple-dose pharmacokinetics of a new acyclovir prodrug, 256U87, in healthy volunteers (abstract). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, September 29, 1991, Chicago, IL."},{"key":"bibr9-106002809202600720","unstructured":"Sherman J, Devault A, Natarajan C, Harkins J, Hedden B, Stouffer B,  SQ 32,756 (BV-araU): characteristics and pharmacokinetics in healthy young and elderly male volunteers (abstract). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 21, 1990, Atlanta, GA."},{"key":"bibr10-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-112-3-187"},{"key":"bibr11-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-1-19"},{"key":"bibr12-106002809202600720","first-page":"S1","volume":"36","author":"Centers for Disease Control","year":"1987","journal-title":"MMWR"},{"key":"bibr13-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112103052403"},{"key":"bibr14-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601163140303"},{"key":"bibr15-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-6-783"},{"key":"bibr16-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-6-823"},{"key":"bibr17-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902023200506"},{"key":"bibr18-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1375"},{"key":"bibr19-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-9-710"},{"key":"bibr20-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440120084042"},{"key":"bibr21-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/161.6.1078"},{"key":"bibr22-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108223250805"},{"key":"bibr23-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-76-3-112-6-416"},{"key":"bibr24-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-4-585"},{"key":"bibr25-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03350010038020"},{"key":"bibr26-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1989.01070010077031"},{"key":"bibr27-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.Supplement_3.S532"},{"key":"bibr28-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_7.S727"},{"key":"bibr29-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1177\/106002808902300101"},{"key":"bibr30-106002809202600720","first-page":"613","volume":"9","author":"Pau AK","year":"1990","journal-title":"Clin Pharm"},{"key":"bibr31-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/10.Supplement_3.S495"},{"key":"bibr32-106002809202600720","unstructured":"Spector SA, Barker C, Buhles W, Feinberg J, Montague P, Weingeist T,  A randomized, controlled study of immediate vs deferred ganciclovir therapy in AIDS patients with cytomegalovirus peripheral retinitis (abstract). Presented at the 7th International Conference on AIDS, June 16, 1991, Florence, Italy."},{"key":"bibr33-106002809202600720","unstructured":"Dieterich D, Kotler D, Busch D, Crumpacker C, Mastre B, Du Mond C,  Randomized, placebo-controlled study of ganciclovir treatment of cytomegalovirus colitis in AIDS patients (abstract). Presented at the 6th International Conference on AIDS, June 23, 1990, San Francisco, CA."},{"key":"bibr34-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-2-111"},{"key":"bibr35-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1084\/jem.169.3.933"},{"key":"bibr36-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.1.43"},{"key":"bibr37-106002809202600720","first-page":"S22","volume":"4","author":"Hardy WD","year":"1991","journal-title":"J Acquir Immune Defic Synd"},{"key":"bibr38-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32900-9"},{"key":"bibr39-106002809202600720","unstructured":"Polsky B, Wolitz R, Chuang EL, Cantrill H, Heinemann MH, Sands M,  Intravitreal ganciclovir salvage therapy for CMV retinitis (ACTG 085): a preliminary report. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, September 29, 1991, Chicago, IL."},{"key":"bibr40-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902023200505"},{"key":"bibr41-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1177\/106002809102500109"},{"key":"bibr42-106002809202600720","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141010-00009"},{"key":"bibr43-106002809202600720","unstructured":"Fletcher CV, Rhame F, Zabinski RA, Edgar C, Beatty C, Noormohamed SE,  Pharmacokinetics and anti-HIV activity of foscamet (abstract). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, October 21, 1990, Atlanta, GA."},{"key":"bibr44-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.3.569"},{"key":"bibr45-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32824-7"},{"key":"bibr46-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.5.736"},{"key":"bibr47-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199005000-00002"},{"key":"bibr48-106002809202600720","unstructured":"Gentilini M, Dohin E, Cochereau I, Brancon C, Caumes E, Bricaire F,  Foscamet in acute therapy of CMV retinitis: experience with twice daily intermittent regimen (abstract). Presented at the 7th International Conference on AIDS, June 16, 1991, Florence, Italy."},{"key":"bibr49-106002809202600720","unstructured":"Ussery FM, Redding K, Rulewski N, Martin-Munley S, Conklin R, Gathe JJr,  The indications, use, efficacy, and safety of foscamet in the treatment of cytomegalovirus retinitis (abstract). Presented at the 7th International Conference on AIDS, June 16, 1991, Florence, Italy."},{"key":"bibr50-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-665"},{"key":"bibr51-106002809202600720","unstructured":"Jacobson MA, Wulfsohn M, Feinberg J, Davis R, Power M, Crumpacker CS. Phase II dose-ranging study of foscamet salvage therapy for CMV retinitis in patients intolerant of or resistant to ganciclovir therapy (ACTG protocol 093). In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, September 29, 1991, Chicago, IL."},{"key":"bibr52-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201233260401"},{"key":"bibr53-106002809202600720","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-4-332_1"},{"key":"bibr54-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-5-1130"},{"key":"bibr55-106002809202600720","unstructured":"Martin-Munley S, Williams P, Rulewski N. Risk factors associated with seizures among patients receiving foscavir (foscamet sodium IV) (abstract). Presented at the 7th International Conference on AIDS, June 16, 1991, Florence, Italy."},{"key":"bibr56-106002809202600720","unstructured":"Metroka CE, Josefberg H. Usefulness of high-dose acyclovir as prophylaxis for CMV (abstract). Presented at the 6th International Conference on AIDS, June 23, 1990, San Francisco, CA."},{"key":"bibr57-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801143180202"},{"key":"bibr58-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.5.938"},{"key":"bibr59-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112053252303"},{"key":"bibr60-106002809202600720","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.3.548"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809202600720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809202600720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:53Z","timestamp":1777374353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809202600720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,7]]},"references-count":60,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[1992,7]]}},"alternative-id":["10.1177\/106002809202600720"],"URL":"https:\/\/doi.org\/10.1177\/106002809202600720","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,7]]}}}